Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Oncurie
AddedFeb 19, 2024
UpdatedJun 18, 2026
Oncurie

Oncurie

Oncurie, a Raleigh-based software startup, innovates radionuclide tech for metastatic cancer cure.

HQ
Raleigh, NC, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Oncurie, a startup company based in Raleigh, North Carolina, was spun out of NC State University with the core mission of creating a cure for metastatic cancer. The company focuses on developing innovative radiotherapeutic agents using novel molecular radionuclide technology. This approach aims to address the significant challenge of metastatic cancer, which remains a leading cause of death due to its ability to evolve and resist conventional treatments. Oncurie's market focus is primarily on the healthcare sector, targeting advanced cancer treatment solutions.

Notable affiliated individuals include researchers and experts from NC State University who have contributed to the foundational technology. The company has garnered attention from investors interested in groundbreaking cancer therapies. Key achievements include the development of proprietary radionuclide technology that shows promise in preclinical studies. Overall, Oncurie has made a significant impact by advancing potential treatments for metastatic cancer, offering hope for more effective and targeted cancer therapies in the future.

Oncurie - Similar Companies

Radionetics Oncology logo

Radionetics Oncology

radionetics.com

Mariana Oncology logo

Mariana Oncology

Aktis Oncology logo

Aktis Oncology

aktisoncology.com

Gradient Medical logo

Gradient Medical

Oncotect logo

Oncotect

oncotect.co

Fuse Oncology logo

Fuse Oncology

fuseonc.com

Novocure logo

Novocure

novocure.com

Oncora Medical logo

Oncora Medical

oncoramedical.com

Oncospace logo

Oncospace

oncospace.com

OnKure Therapeutics logo

OnKure Therapeutics

OncXerna Therapeutics logo

OncXerna Therapeutics

oncxerna.com

OncoTrap logo

OncoTrap

OncoResponse logo

OncoResponse

Curelab Oncology logo

Curelab Oncology

Civatech Oncology logo

Civatech Oncology

Oncurie - Quick Facts

Who are Oncurie's competitors?

Companies similar to Oncurie include Radionetics Oncology, Mariana Oncology, Aktis Oncology and Gradient Medical.

When was Oncurie founded?

Oncurie was founded in 2021.

Where is Oncurie's headquarters located?

Oncurie's headquarters is located in Raleigh, NC, US.

When was Oncurie's last funding round?

Oncurie's most recent funding round was for $75k (USD) in September 2022.

How much has Oncurie raised to-date?

As of Sep 22, 2022, Oncurie has raised a total of $330.7k (USD).

How many employees does Oncurie have?

Oncurie has 1 employee as of Feb 4, 2024.

Oncurie - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Radiotherapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software